Experimental study of antitumor effect of 1,2:5,6-dianhydro-3,4-diacetylgalactitol against tumor

Objective To evaluate the effects of antitumor of 1,2:5,6-dianhydro-3,4-diacetylgalactitol (DADAG) chemotherapy in vitro and in vivo. Methods The antiproliferative activity of DADAG for tumor cell strain in vitro using MTT assay and the antitumor effect of DADAG in vivo using intracerebrally inoculated.Ehrlich ascites carcinoma(EAC) or L1210 leukemia in mice were observed. Results DADAG had potential antiproliferative activity on human HL-60 cells and K562 cells,the IC 50 value was 3.7?μg·ml -1 and 25.5?μg·ml -1 ,respectively. The high dose of DADAG(10.0?mg·kg -1 ,ip) inhibited intracerebrally inoculated EAC in mice, and the increase of life span(ILS) was 30%(P0.05 ). While DADAG at doses of 6.4?mg·kg -1 , 8.0?mg·kg -1 and 10.0?mg·kg -1 exhibited significantly inhibitory effects on intracerebrally inoculated L1210 leukimia in mice compared with NS treatment,the ILSes were 35%,47% and 55%(P0.01,respectively).Conclusion DADAG possesses potential antitumor activity in vitro and in vivo.